Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

被引：0
|
作者：
Ignacio Bernabéu
Carmen Fajardo
Mónica Marazuela
Fernando Cordido
Eva María Venegas
Pedro de Pablos-Velasco
Gonzalo Piedrola Maroto
María Pilar Olvera
Isabel Pavón de Paz
Davide Carvalho
Carme Romero
Guillermo De la Cruz
Cristina Álvarez Escolá
机构：
[1] Hospital Clínico Universitario Santiago de Compostela,Endocrinology and Nutrition Department
[2] Hospital Universitario de La Ribera,Endocrinology and Nutrition Department
[3] Hospital Universitario La Princesa,Endocrinology and Nutrition Department
[4] Universidad Autónoma Madrid,Faculty of Health Sciences and INIBIC, University of A Coruña, and Endocrinology and Nutrition Department
[5] Instituto Princesa,Endocrinology and Nutrition Department
[6] Complejo Hospitalario Universitario de A Coruña,Endocrinology and Nutrition Department
[7] Hospital Universitario Virgen del Rocío,Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário São João
[8] University of Las Palmas de Gran Canaria. Spain,Endocrinology and Nutrition Department
[9] Endocrinology and Nutrition Departament Hospital Universitario Virgen de las Nieves,undefined
[10] Endocrinology and Nutrition Departament,undefined
[11] Hospital Universitario Nuestra Señora de Candelaria,undefined
[12] Endocrinology and Nutrition Departament,undefined
[13] Hospital Universitario de Getafe,undefined
[14] Faculty of Medicine,undefined
[15] i3S,undefined
[16] Universidade do Porto,undefined
[17] Adknoma Health Research S.L.,undefined
[18] Ipsen Pharma,undefined
[19] Hospital Universitario La Paz,undefined
来源：
Endocrine | 2020年 / 70卷
关键词：
Acromegaly; Lanreotide; Insulin-like growth factor 1; Somatostatin; Growth hormone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：575 / 583
页数：8
相关论文
共 50 条
  • [31] Somatuline Autogel: an extended release lanreotide formulation
    Lightman, S
    HOSPITAL MEDICINE, 2002, 63 (03): : 162 - 165
  • [32] Lanreotide Autogel 120 mg As a Treatment for Chronic Idiopathic Refractory Diarrhea : A Multicenter Prospective Trial
    Bisschops, Raf
    De Ruyter, Vincent
    Demolin, Gauthier
    Baert, Didier
    Moreels, Tom G.
    Pattyn, Piet
    Verhelst, Hans
    Lepoutre, Luc
    Arts, Joris
    Ooghe, Patrick
    Caenepeel, Philip
    Maisonobe, Pascal
    Tack, Jan F.
    GASTROENTEROLOGY, 2014, 146 (05) : S72 - S72
  • [33] Dosage and costs of lanreotide Autogel 120 mg administered as part of routine acromegaly care in Poland - two years of data from Lanro-Study
    Orlewska, Ewa
    Kos-Kudla, Beata
    Sowinski, Jerzy
    Sworczak, Krzysztof
    Zgliczynski, Wojciech
    ENDOKRYNOLOGIA POLSKA, 2015, 66 (02) : 142 - 148
  • [34] Efficacy and Safety of Co-Administration of Lanreotide Autogel 120 mg Monthly with Pegvisomant Weekly in Patients with Acromegaly Partially Controlled by Somatostatin Analogues.
    van der Lely, A-J
    Bernabeu, I.
    Cap, J.
    Caron, P.
    Colao, A.
    Lesage, C.
    Marek, J.
    Neggers, S. J. C. M. M.
    Birman, P.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [35] Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective
    Bevan, J. S.
    Newell-Price, J.
    Wass, J. A. H.
    Atkin, S. L.
    Bouloux, P. M.
    Chapman, J.
    Davis, J. R. E.
    Howlett, T. A.
    Randeva, H. S.
    Stewart, P. M.
    Viswanath, A.
    CLINICAL ENDOCRINOLOGY, 2008, 68 (03) : 343 - 349
  • [36] Sustained biochemical control in patients with acromegaly treated with lanreotide depot 120 mg administered every 4 weeks, or an extended dosing interval of 6 or 8 weeks: a pharmacokinetic approach
    Gomez-Panzani, Edda
    Chang, Stephen
    Ramis, Joaquim
    Landolfi, Michelle M.
    Bakker, Bert
    RESEARCH AND REPORTS IN ENDOCRINE DISORDERS, 2012, 2 : 79 - 84
  • [37] The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR
    Ashwell, SG
    Bevan, JS
    Edwards, OM
    Harris, MM
    Holmes, C
    Middleton, MA
    James, RA
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 150 (04) : 473 - 480
  • [38] Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review
    Mazziotti, Gherardo
    Giustina, Andrea
    PITUITARY, 2010, 13 (01) : 60 - 67
  • [39] Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review
    Gherardo Mazziotti
    Andrea Giustina
    Pituitary, 2010, 13 : 60 - 67
  • [40] A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly
    M. Fleseriu
    Z. Zhang
    K. Hanman
    K. Haria
    A. Houchard
    S. Khawaja
    A. Ribeiro-Oliveira
    M. Gadelha
    Pituitary, 2023, 26 : 9 - 41
12345